Clinical Research Directory
Browse clinical research sites, groups, and studies.
Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
Sponsor: Alaunos Therapeutics
Summary
This an an open-label study to define the safety profile and the maximum tolerated dose and confirm the clinical effective dose of palifosfamide-tris given intravenously in combination with etoposide and carboplatin in a wide range of cancers which etoposide and carboplatin are normally given. Once the maximum dose of palifosfamide-tris is determined,a Phase II study using the 3 agents combined will begin.
Official title: A Phase I Study of Intravenous (IV) Palifosfamide-tris Administered in Combination With IV Etoposide and IV Carboplatin in Patients With Malignancies for Which Etoposide and Carboplatin Are an Appropriate Choice
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
22
Start Date
2010-12
Completion Date
2012-07-16
Last Updated
2026-09-29
Healthy Volunteers
No
Conditions
Interventions
palifosfamide-tris
Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
Locations (4)
Indiana University Simon Cancer Center
Indianapolis, Indiana, United States
Horizon Oncology Research
Lafayette, Indiana, United States
Medical Consultants, PC
Muncie, Indiana, United States
Washington University
St Louis, Missouri, United States